Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Add To Watchlist

Recent & Breaking News (NYSE:PFE)

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

Business Wire July 31, 2018

Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Business Wire July 31, 2018

Pfizer's New Report Shows How Behavioural Science Can Help Boost Preventative Healthcare Measures

PR Newswire Europe Non Regulatory July 31, 2018

Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs

Business Wire July 24, 2018

ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018

Business Wire July 24, 2018

ViiV Healthcare Presents Phase III Data at AIDS 2018 from Landmark GEMINI Studies Showing Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïve HIV Patients, with No Emergence of Resistance

Business Wire July 24, 2018

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)

Business Wire July 20, 2018

Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

Business Wire July 18, 2018

Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy

Business Wire July 16, 2018

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Business Wire July 13, 2018

Pfizer to Organize for Future Growth

Business Wire July 11, 2018

Pfizer’s Announces It Will Defer Company’s Price Increases

Business Wire July 10, 2018

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis

Business Wire June 28, 2018

Pfizer Declares 34-Cent Third-Quarter 2018 Dividend

Business Wire June 28, 2018

U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia

Business Wire June 27, 2018

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer

Business Wire June 25, 2018

Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts

Business Wire June 19, 2018

Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness

Business Wire June 12, 2018

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

Business Wire June 7, 2018

Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures

Business Wire June 6, 2018